Quantifying the treatment efficacy of reverse transcriptase inhibitors: new analyses of clinical data based on within-host modeling

Breban, Romulus; Napravnik, Sonia; Kahn, James; Blower, Sally
January 2009
BMC Public Health;2009 Supplement 1, Vol. 9, Special section p1
Academic Journal
Background: Current measures of the clinical efficacy of antiretroviral therapy (ART) in the treatment of HIV include the change in HIV RNA in the plasma and the gain in CD4 cells. Methods: We propose new measures for evaluating the efficacy of treatment that is based upon combinations of non-nucleoside and nucleoside reverse transcriptase inhibitors. Our efficacy measures are: the CD4 gain per virion eliminated, the potential of CD4 count restoration and the viral reproduction number (R0). These efficacy measures are based upon a theoretical understanding of the impact of treatment on both viral dynamics and the immune reconstitution. Patient data were obtained from longitudinal HIV clinical cohorts. Results: We found that the CD4 cell gain per virion eliminated ranged from 10-2 to 600 CD4 cells/virion, the potential of CD4 count restoration ranged from 60 to 1520 CD4 cells/µl, and the basic reproduction number was reduced from an average of 5.1 before therapy to an average of 1.2 after one year of therapy. There was substantial heterogeneity in these efficacy measures among patients with detectable viral replication. We found that many patients who achieved viral suppression did not have high CD4 cell recovery profiles. Our efficacy measures also enabled us to identify a subgroup of patients who were not virally suppressed but had the potential to reach a high CD4 count and/or achieve viral suppression if they had been switched to a more potent regimen. Conclusion: We show that our new efficacy measures are useful for analyzing the long-term treatment efficacy of combination reverse transcriptase inhibitors and argue that achieving a low R0 does not imply achieving viral suppression.


Related Articles

  • Pharmacology of Current and Investigational Human Immunodeficiency virus (HIV) Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Adults. Laura Waters; Marta Boffito // Anti-Infective Agents in Medicinal Chemistry;2007, Vol. 6 Issue 3, p213 

    Since the mid-1980s, the nucleoside reverse transcriptase inhibitors (NRTIs) have established their position as valuable antiretroviral (ARV) agents in the treatment of human immunodeficiency virus (HIV) infection. Today, NRTIs still constitute the �backbone� of highly active ARV...

  • Etravirine: A Guide to Its Use in Treatment-Experienced Pediatric Patients with HIV-1 Infection in the US. Lyseng-Williamson, Katherine A. // Pediatric Drugs;2012, Vol. 14 Issue 5, p345 

    Etravirine (Intelence®), an oral next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), is approved for the treatment of HIV-1 infection in treatment-experienced patients. In the US, the approved use of etravirine in patients who have evidence of viral replication and harbor...

  • A Review on Novel Formulation Approaches of Azidothymidine. Nath, Jayalakshmi; Hari, B. N. Vedha; Devi, D. Ramya // Journal of Pharmaceutical Sciences & Research;2013, Vol. 5 Issue 7, p140 

    Azidothymidine (AZT or ZVD), a Nucleoside Reverse Transcriptase Inhibitor (NRTI), is used as antiviral medication to treat Human Immunodeficiency Virus (HIV) which causes Acquired Immunodeficiency Syndrome (AIDS). It is the first approved anti HIV drug for AIDS used either in combination with...

  • Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Triple Combination Tablet. Arribas, Jose R. // Drugs;2006, Vol. 66 Issue 11, p1513 

    The article reports on the triple combination tablets of efavirenz/emtricitabine/tenofovir disoproxil fumarate. The tablets are used to treat human immunodeficiency viruses (HIV). The drugs belong to the category of antiretrovirals. Tenofovir is a potent nucleotide reverse transcriptase...

  • Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Triple Combination Tablet. Volberding, Paul // Drugs;2006, Vol. 66 Issue 11, p1514 

    The article reports on the triple combination tablets of efavirenz/emtricitabine/tenofovir disoproxil fumarate. The antiretroviral therapy in human immunodeficiency viruses infection made a significant development with the creation of the three-drug combinations. The three-drug tablets are...

  • Azvudine, A Novel Nucleoside Reverse Transcriptase Inhibitor Showed Good Drug Combination Features and Better Inhibition on Drug-Resistant Strains than Lamivudine In Vitro. Wang, Rui-Rui; Yang, Qing-Hua; Luo, Rong-Hua; Peng, You-Mei; Dai, Shao-Xing; Zhang, Xing-Jie; Chen, Huan; Cui, Xue-Qing; Liu, Ya-Juan; Huang, Jing-Fei; Chang, Jun-Biao; Zheng, Yong-Tang // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Azvudine is a novel nucleoside reverse transcriptase inhibitor with antiviral activity on human immunodeficiency virus, hepatitis B virus and hepatitis C virus. Here we reported the in vitro activity of azvudine against HIV-1 and HIV-2 when used alone or in combination with other antiretroviral...

  • Antiviral Profile of HIV Inhibitors in Macrophages: Implications for Therapy. Perno, C.-F.; Balestra, E.; Francesconi, M.; Abdelahad, D.; Caliò, R.; Balzarini, J.; Aquaro, S. // Current Topics in Medicinal Chemistry;May2004, Vol. 4 Issue 9, p1009 

    Macrophages (M / M) are identified as the second cellular target of HIV and a crucial virus reservoir. M / M are persistently infected cells and not susceptible to the HIV cytophatic effects typical of infected CD4+ T-lymphocytes. HIV replication in M / M is a crucial pathogenetic event during...

  • New tools to track HIV. Schacker, Timothy // Nature Medicine;Apr2010, Vol. 16 Issue 4, p373 

    The article comments on a study published within the issue on the role of HIV drug raltegravir for low-level replication that blocks integration of viral linear cDNA into genomic host cell DNA. It discusses the study of 69 HIV-positive individuals which states that subjects randomized to a group...

  • NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2012, p610 

    The article presents information on nucleoside reverse transcriptase inhibitors, including their dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics